Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With Relapsed or Refractory Malignant Mesothelioma With BAP1 Loss of Function

NCT02860286 is registered in ClinicalTrials.gov with Epizyme, Inc. as lead sponsor.

NCT NCT02860286
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02860286 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With Relapsed or Refractory Malignant Mesothelioma With BAP1 Loss of Function
Lead sponsor
Epizyme, Inc.
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2016
Completion date
May 31, 2019
Enrollment
74 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

bap1 loss of function, mesothelioma